Loading...
EXENS logo

ExosensENXTPA:EXENS Stok Raporu

Piyasa Değeri €3.3b
Hisse Fiyatı
€64.60
€67.13
3.8% değerinin altında içsel indirim
1Y61.7%
7D11.8%
1D
Portföy Değeri
Görünüm

Exosens

ENXTPA:EXENS Stok Raporu

Piyasa değeri: €3.3b

Exosens (EXENS) Hisse Özeti

Exosens, Fransa, Avrupa'nın geri kalanı, Kuzey Amerika, Asya, Okyanusya, Afrika ve uluslararası alanda amplifikasyon, algılama ve görüntüleme alanlarında elektro-optik teknolojilerin geliştirilmesi, üretimi ve satışı ile ilgilenmektedir. Daha fazla detay

EXENS Community Fair Values

Create Narrative

See what 27 others think this stock is worth. Follow their fair value or set your own to get alerts.

Exosens Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Exosens
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı€64.60
52 Haftanın En Yüksek Seviyesi€74.00
52 Haftanın En Düşük Seviyesi€36.20
Beta0
1 Aylık Değişim-0.39%
3 Aylık Değişim5.04%
1 Yıllık Değişim61.70%
3 Yıllık Değişimn/a
5 Yıllık Değişimn/a
Halka arzdan bu yana değişim187.11%

Son Haberler & Güncellemeler

Anlatı Güncellemesi May 09

EXENS: Defense Backlog And Higher P E Range Will Shape Upside Outlook

Exosens' updated analyst price target has edged higher by about €0.30, with the adjustment supported by recent target increases from Berenberg, JPMorgan, Deutsche Bank and Citi. These changes reflect refreshed assumptions on growth, profitability and P/E multiples.
Anlatı Güncellemesi Apr 24

EXENS: Defense Backlog And Rich P E Will Shape Balanced Outlook

Exosens' analyst price target has been lifted, with the fair value estimate moving by €2 to €66.83 as analysts broadly raise their targets into a future P/E of about 32.8x, citing updated views reflected in recent price target increases from multiple banks. Analyst Commentary Recent research points to a cluster of higher targets around the current fair value estimate, with price objectives now ranging from €55 to €71.

Recent updates

Anlatı Güncellemesi May 09

EXENS: Defense Backlog And Higher P E Range Will Shape Upside Outlook

Exosens' updated analyst price target has edged higher by about €0.30, with the adjustment supported by recent target increases from Berenberg, JPMorgan, Deutsche Bank and Citi. These changes reflect refreshed assumptions on growth, profitability and P/E multiples.
Anlatı Güncellemesi Apr 24

EXENS: Defense Backlog And Rich P E Will Shape Balanced Outlook

Exosens' analyst price target has been lifted, with the fair value estimate moving by €2 to €66.83 as analysts broadly raise their targets into a future P/E of about 32.8x, citing updated views reflected in recent price target increases from multiple banks. Analyst Commentary Recent research points to a cluster of higher targets around the current fair value estimate, with price objectives now ranging from €55 to €71.
Anlatı Güncellemesi Apr 10

EXENS: Defense Contracts And Higher Future P E Assumptions Will Support Earnings Power

Exosens' updated analyst price target has shifted from €61.00 to €75.00. This reflects analysts' revised fair value views, supported by a series of recent target increases from major banks citing their latest assessments on growth, profitability and P/E assumptions.
Anlatı Güncellemesi Mar 27

EXENS: Defense Backlog And New Shareholder Support Will Shape Balanced Outlook

Exosens' analyst price targets have moved higher, with recent updates ranging from about €55 to €71 as analysts factor in their latest views on growth, margins and valuation multiples, while the model's fair value estimate remains steady at €64.83. Analyst Commentary Recent Street research on Exosens clusters around higher price targets in a relatively tight band, giving you a clearer sense of how the market is framing potential risk and reward.
Anlatı Güncellemesi Mar 12

EXENS: Defense Contracts And New Shareholder Support Will Underpin Measured Outlook

Exosens' analyst price target has been revised higher to €64.83 from €51.33, reflecting updated assumptions on revenue growth, profit margins, and future P/E in line with recent price target increases from several banks including JPMorgan, Deutsche Bank, Citi, and Berenberg. Analyst Commentary Recent research shows a cluster of higher price targets on Exosens, with JPMorgan at the upper end and several other banks setting targets in a similar range.
Anlatı Güncellemesi Feb 22

EXENS: Future Defense Contracts Will Still Reveal Extended Overvaluation Risk

Analysts have nudged their price target on Exosens slightly higher to €39.06 from €38.30, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E, which together support a modest uplift in estimated fair value. What's in the News Theon International completed the acquisition of a 9.8% stake in Exosens for about €268.7 million at €54 per share, making Theon the second largest shareholder after Groupe HLD, following regulatory clearances and closing on January 7, 2026 (Key Developments).
Anlatı Güncellemesi Feb 07

EXENS: Defense Contracts And New Shareholder Support Will Strengthen Future Earnings Power

Analysts have maintained their price target for Exosens at €61.00. They cite only minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions, which they view as offsetting one another.
Anlatı Güncellemesi Jan 24

EXENS: Long Term Defense Contracts Will Drive Future Earnings Power Higher

Analysts now set their fair value estimate for Exosens at $61.00, compared with the prior $60.00, citing adjusted assumptions around discount rate, revenue growth, profit margin, and future P/E as key drivers of the change. What's in the News Theon International Plc completed the acquisition of a 9.8% stake in Exosens for approximately €268.7 million at €54 per share, becoming the second largest shareholder after Groupe HLD (M&A Transaction Closings).
Anlatı Güncellemesi Jan 10

EXENS: Future Defense Contracts Will Expose Overvaluation Risk Despite Extended Supply Agreement

Analysts have raised their price target on Exosens to about $38.30 from $33.50, citing updated assumptions for fair value, discount rate, revenue, profit margin and future P/E that they see as better reflecting the company’s current outlook. What's in the News Theon International completed the acquisition of a 9.8% stake in Exosens from Invest Gamma, HLD Europe S.C.A. and Invest Prince Henri SCA for about €268.7 million at €54 per share.
Anlatı Güncellemesi Dec 26

EXENS: German Defense Contract Will Drive Earnings Power Higher

Analysts have raised their price target on Exosens from 50.50 dollars to 60.00 dollars, citing expectations for slightly faster revenue growth, modestly higher profit margins, and a richer future earnings multiple supported by a marginally lower discount rate. What's in the News Exosens and Theon International secured a landmark OCCAR contract to supply 100,000 Mikron binocular devices embedding 200,000 16mm tubes for the German Armed Forces and additional devices for Belgium, a deal valued at more than EUR 500 million and described as likely the largest night vision contract ever concluded globally (Key Developments).
Anlatı Güncellemesi Dec 12

EXENS: Extended Defense Contracts And Equity Stake Will Support Steady Outlook

Analysts have raised their price target on Exosens from approximately $49.67 to $51.33, citing a modestly lower discount rate and slightly higher expected future valuation multiples, despite marginally softer revenue growth and profit margin assumptions. What's in the News Exosens and Theon International extended their long term commercial agreement for Image Intensifier Tubes by three years to cover potential deliveries through 2030, with Theon set to convert 2027 and 2028 options into firm orders and increase its annual purchase volumes (company announcement).
Anlatı Güncellemesi Nov 28

EXENS: Major Defense Contract Will Drive Demand Momentum Through 2028

Analysts have slightly adjusted their price target for Exosens, maintaining it at $49.67. The updated expectations reflect a marginal decrease in projected revenue growth, which is offset by a modest improvement in anticipated profit margins.
Anlatı Güncellemesi Nov 13

EXENS: Recent Stake Acquisition and Defense Contract Will Shape Outlook Through 2028

Analysts have raised their price target for Exosens from $48.67 to $49.67, citing improved revenue growth forecasts and a slightly lower discount rate as key factors behind the increase. What's in the News Theon International Plc entered into a definitive agreement to acquire a 9.8% stake in Exosens for approximately €270 million, making Theon the second largest shareholder upon completion.
Anlatı Güncellemesi Oct 30

EXENS: Defense Sector Demand And Shareholder Shift Will Shape Outlook

Analysts have raised their price target for Exosens from $47.56 to $48.67, citing incremental improvements in revenue growth, profit margins, and future earnings expectations. What's in the News Theon International Plc has entered into a definitive agreement to acquire a 9.8% stake in Exosens for approximately €270 million, which would make Theon the second largest shareholder, pending regulatory approval.
Analiz Makalesi Oct 27

Calculating The Intrinsic Value Of Exosens (EPA:EXENS)

Key Insights Exosens' estimated fair value is €53.11 based on 2 Stage Free Cash Flow to Equity Exosens' €47.50 share...
Anlatı Güncellemesi Oct 16

Rising NATO Spending Will Boost Night Vision And Advanced Sensing

Analysts have raised their price target for Exosens from $45.50 to $47.56, citing expectations of slightly stronger revenue growth and higher future valuation multiples. What's in the News Theon International Plc has agreed to acquire a 9.8% stake in Exosens for approximately €270 million, becoming the company's second largest shareholder.
Analiz Makalesi Sep 15

Exosens (EPA:EXENS) Seems To Use Debt Quite Sensibly

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Anlatı Güncellemesi Sep 10

Rising NATO Spending Will Boost Night Vision And Advanced Sensing

Despite a reduction in consensus revenue growth forecasts, the valuation multiple for Exosens SAS has increased, driving the analyst price target up from €42.57 to €45.50. What's in the News Exosens announces a share repurchase program of up to 240,000 shares, intended to cover performance share plans for employees, with an expiration date of October 31, 2025.
Anlatı Güncellemesi Aug 08

Rising NATO Spending Will Boost Night Vision And Advanced Sensing

With no significant changes in Exosens' discount rate or future P/E, the consensus analyst price target remained steady at €42.57. What's in the News Exosens announces a share repurchase program for up to 240,000 shares, with repurchased shares to be used for employee performance share plans and offer expiring on October 31, 2025.
Analiz Makalesi Aug 03

Exosens (EPA:EXENS) Released Earnings Last Week And Analysts Lifted Their Price Target To €41.21

It's been a good week for Exosens ( EPA:EXENS ) shareholders, because the company has just released its latest...
Analiz Makalesi Jul 25

Exosens' (EPA:EXENS) Intrinsic Value Is Potentially 26% Above Its Share Price

Key Insights The projected fair value for Exosens is €50.06 based on 2 Stage Free Cash Flow to Equity Current share...
Analiz Makalesi Jul 06

Exosens (EPA:EXENS) Might Have The Makings Of A Multi-Bagger

What trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...
Analiz Makalesi Jun 13

Exosens (EPA:EXENS) Seems To Use Debt Quite Sensibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
User avatar
Yeni Anlatı Jun 08

Elevated Defense Spending Will Challenge Overvaluation And Unleash Upside

Growth and profitability expectations rely on sustained global defense spending, rapid demand capture, and seamless operational execution, making them vulnerable to defense cycle shifts and integrati
Analiz Makalesi May 29

Market Participants Recognise Exosens' (EPA:EXENS) Revenues Pushing Shares 27% Higher

Exosens ( EPA:EXENS ) shares have continued their recent momentum with a 27% gain in the last month alone. Longer-term...
Analiz Makalesi Mar 06

€31.58 - That's What Analysts Think Exosens (EPA:EXENS) Is Worth After These Results

The investors in Exosens 's ( EPA:EXENS ) will be rubbing their hands together with glee today, after the share price...
Analiz Makalesi Mar 05

Optimistic Investors Push Exosens (EPA:EXENS) Shares Up 37% But Growth Is Lacking

Exosens ( EPA:EXENS ) shares have continued their recent momentum with a 37% gain in the last month alone. Longer-term...
Analiz Makalesi Feb 14

Exosens' (EPA:EXENS) Intrinsic Value Is Potentially 96% Above Its Share Price

Key Insights The projected fair value for Exosens is €42.30 based on 2 Stage Free Cash Flow to Equity Exosens' €21.56...

Hissedar Getirileri

EXENSFR Aerospace & DefenseFR Pazar
7D11.8%3.4%2.0%
1Y61.7%5.1%1.3%

Getiri vs. Endüstri: EXENS geçen yıl % 5.1 oranında getiri sağlayan French Aerospace & Defense sektörünü aştı.

Getiri vs Piyasa: EXENS geçen yıl % 1.3 oranında getiri sağlayan French Piyasasını aştı.

Fiyat Oynaklığı

Is EXENS's price volatile compared to industry and market?
EXENS volatility
EXENS Average Weekly Movement7.2%
Aerospace & Defense Industry Average Movement6.8%
Market Average Movement5.4%
10% most volatile stocks in FR Market10.7%
10% least volatile stocks in FR Market2.9%

İstikrarlı Hisse Senedi Fiyatı: EXENS son 3 ayda French piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: EXENS 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
19371,499Jerome Cerisierwww.exosens.com

Exosens, Fransa, Avrupa'nın geri kalanı, Kuzey Amerika, Asya, Okyanusya, Afrika ve uluslararası alanda amplifikasyon, algılama ve görüntüleme alanlarında elektro-optik teknolojilerin geliştirilmesi, üretimi ve satışı ile ilgilenmektedir. Görüntü yoğunlaştırıcı tüpler; ultra viyole, kısa ve uzun dalga kızılötesi, görünür - yakın kızılötesi ve orta dalga kızılötesi kameraların yanı sıra gelişmiş görüş ekipmanları; iyon ve elektron, sintilasyon ve tek foton algılama ürünleri; x-ışını bileşenleri, nötronik görüntüleme ürünleri ve bilimsel uygulamalar için görüntü yoğunlaştırıcılar; ve gama ve nötron dedektörleri ve mineral yalıtımlı uzantılar sunar. Şirket ayrıca güç tüpleri ve mikrodalga cihazları; ve metan havadan algılama çözümleri sunmaktadır.

Exosens Temel Bilgiler Özeti

Exosens'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
EXENS temel i̇stati̇sti̇kler
Piyasa değeri€3.27b
Kazançlar(TTM)€70.19m
Gelir(TTM)€468.19m
46.7x
F/K Oranı
7.0x
P/S Oranı

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
EXENS gelir tablosu (TTM)
Gelir€468.19m
Gelir Maliyeti€186.99m
Brüt Kâr€281.19m
Diğer Giderler€211.00m
Kazançlar€70.19m

Son Raporlanan Kazançlar

Dec 31, 2025

Sonraki Kazanç Tarihi

Jul 28, 2026

Hisse başına kazanç (EPS)1.38
Brüt Marj60.06%
Net Kâr Marjı14.99%
Borç/Özkaynak Oranı56.1%

EXENS uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

0.5%
Mevcut Temettü Verimi
22%
Ödeme Oranı

EXENS güvenilir bir temettü ödüyor mu?

EXENS temettü geçmişine ve kıyaslamalara bakın
Yaklaşan bir temettüyü almak için ne zaman EXENS satın almanız gerekir?
Exosens temettü tari̇hleri̇
Eski Temettü TarihiMay 27 2026
Temettü Ödeme TarihiMay 29 2026
Eski temettüye kadar geçen günler4 days
Temettü ödeme tarihine kadar geçen günler6 days

EXENS güvenilir bir temettü ödüyor mu?

EXENS temettü geçmişine ve kıyaslamalara bakın

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/22 08:47
Gün Sonu Hisse Fiyatı2026/05/22 00:00
Kazançlar2025/12/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Exosens 15 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Amelie Dueckelmann-DublanyBerenberg
Aleksander PetercBernstein
Laurent GelebartBNP Paribas